S.Korea approves Zeltia cancer drug Yondelis
MADRID, May 8 (Reuters) - Spain's Zeltia (ZEL.MC: Quote, Profile, Research) said on Thursday its cancer drug Yondelis has been approved for sale in South Korea, pushing shares higher.
Yondelis has been on sale in Europe since last year for treating soft tissue sarcomas, and the company said it expects European sales of 34 million euros ($52.12 million) for the drug this year.
In South Korea, Yondelis will be distributed by Johnson & Johnson (JNJ.N: Quote, Profile, Research), which has non-European marketing rights for the drug and pays royalties to Zeltia.
Zeltia shares were 2.87 percent higher at 5.38 euros at 1241 GMT, while the leading-share Ibex .IBEX index was 0.1 percent lower. (Reporting by Robert Hetz; editing by Sue Thomas)
© Thomson Reuters 2009 All rights reserved
Pledge to support economies
G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured. Full Article | Related Story
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
